A recent modeling study found that allocating kidneys to patients receiving dialysis was a better use of the organs from a societal perspective compared with giving kidneys to those on a preemptive waiting list.
A preemptive waiting list for kidney recipients is not the best use of scarce resources from a societal perspective, and giving kidneys to those receiving dialysis is more effective, according to recent findings that simulated the cases of 4 patients with renal disease.
The aim of the study, published in JAMA Network Open, was to examine patient outcomes and costs when a strategy diverts kidney organs from candidates receiving dialysis and instead gives it to those on a preemptive waiting list. To do this, the medical decision analytical model "followed" 4 patients:
Some assumptions were made for the model, including that the kidney transplanted was the same for both patients; patients in all cohorts were similar in age, sex, race and ethnicity, disease, comorbidity status, and insurance; mortality in patients on the preemptive waiting list was relatively higher compared with patients receiving a preemptive transplant; and mortality in patients who received a transplant after dialysis for less than 1 year was equal to mortality in patients receiving a transplant preemptively.
The baseline patient was aged 50 years, which was the mean age of preemptive patients transplanted with a kidney. Patients were excluded if they had a transplant after 65 years, as most of the preemptive recipients would be younger than 65 years.
The preemptive transplant recipient had 10.58 (95% CI, 10.36-10.80) QALYs and the preemptive patient never transplanted had 6.83 (95% CI, 6.67-6.99) QALYs in the simulated patient with a mean start age of 50 years, which was a gain of 3.75 (95% CI, 3.57-3.93) QALYs.
The patient who had a transplant from dialysis had 10.33 (95% CI, 10.21-10.55) QALYs whereas the dialysis patient that remained on the waiting list had 6.20 (95% CI, 6.04-6.36) QALYs, which is a gain of 4.13 (95% CI, 3.92-4.31) QALYs. The study found that preferential preemptive transplantation had –0.39 (95% CI, –0.59 to –0.29) QALYs and resulted in an added cost of $54,100 (95% CI, $44,100-$64,100) compared with allocation to a waiting list for those already receiving dialysis.
The difference was –0.67 (95% CI, –0.78 to –0.56) QALYs and had a higher net cost of $105,900 (95% CI, $89,700-$122,100) in a preemptive patient that was less likely to need dialysis. The benefit was –0.16 (95% CI, –0.25 to –0.07) QALYs at a net cost of $9200 (95% CI, $1000-$17,400) in patients who were more likely to need dialysis.
Patients who received dialysis for 3 to 4 years had 9.66 (95% CI, 9.44-9.88) QALYs whereas patients in the dialysis group who stayed on the waiting list had 5.92 (95% CI, 5.76-6.08) QALYs, with a benefit of 0.01 (95% CI, –0.13 to 0.15) QALYs for the patient receiving a preemptive transplant.
Net benefit favored preemptive transplantation (0.24 QALYs; 95% CI, 0.10-0.38) if the preemptive patient was more likely to need dialysis but there was a loss of net benefit (–0.27 QALYs; 95% CI, –0.40 to –0.14) if the patient was less likely to need dialysis.
There were some limitations to this study. Individual characteristics were not considered and therefore the results of this study should be confirmed with patient-level data analysis. The analysis was not aimed at determining the threshold for waitlisting patients. The study did not consider that a preemptive patient could be given a kidney based on matching criteria. A suggestion for preferentially allocating organs to patients receiving dialysis for less than a year rather than to patients receiving dialysis for more than a year was not given.
The researchers concluded that preemptive waitlisting may be a strategy that favors some groups over others.
“Rather than eliminating preemptive transplantation, restricting the list to those likely to be on dialysis within a year or who are highly sensitized may be an optimal approach, provided qual access can be assured for all,” the authors wrote.
Reference
Kiberd BA, Tennankore KK, Vinson AJ. Comparing the net benefits of adult deceased donor kidney transplantation for a patient on the preemptive waiting list vs a patient receiving dialysis. JAMA Netw Open. 2022;5(7):e2223325. doi:10.1001/jamanetworkopen.2022.23325
Long-Term Benefits Show the Value of Upfront Investments in Value-Based Care
October 17th 2024Miriam Godwin, CMMI, National Kidney Foundation, touches on the gaps in kidney care that public policy can address, as well as the importance of thinking about the long-term benefits of value-based care.
Read More
More Needs to Be Done to Reduce Racial Disparities in Home Dialysis
March 24th 2023On this episode of Managed Care Cast, we speak with Virginia Wang, PhD, and Matthew L. Maciejewski, PhD, who talk about their recent study on racial disparities in home dialysis, and what more needs to be done to increase uptake and reduce disparities in home dialysis for non-White patients.
Listen
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More